Glatiramer acetate (ga), the immunomodulatory drug, inhibits inflammatory mediators and collagen degradation in osteoarthritis (oa) cartilage

Osteoarthritis and Cartilage

Volumn 19, Issue 9, 2011, Pages 1158-1164

  Attur, M ^a   Millman, J S ^a   Dave, M N ^a   Al Mussawir, H E ^a   Patel, J ^a   Palmer, G ^a   Abramson, S B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Collagen degradation; Glatiramer acetate; Osteoarthritis; Soluble interleukin 1 receptor antagonist (sIL 1Ra)

Indexed keywords

GLATIRAMER; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PROCOLLAGENASE; PROCOLLAGENASE 3; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; OSTEOARTHRITIS; PRIORITY JOURNAL;

AGED; CARTILAGE, ARTICULAR; CHONDROCYTES; COLLAGEN; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; NITRIC OXIDE; OSTEOARTHRITIS, KNEE; PEPTIDES; POLYMERASE CHAIN REACTION;

EID: 80051790762     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.06.006     Document Type: Article

References (35)

1. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58(1):26-35.
2. Chowdhury T.T., Appleby R.N., Salter D.M., Bader D.A., Lee D.A. Integrin-mediated mechanotransduction in IL-1 beta stimulated chondrocytes. Biomech Model Mechanobiol 2006, 5(2-3):192-201.
3. Pelletier J.P., Martel-Pelletier J., Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44(6):1237-1247.
4. Loeser R.F. Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum 2006, 54(5):1357-1360.
5. Goldring M.B., Otero M., Tsuchimochi K., Ijiri K., Li Y. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008, 67(Suppl 3):75-82.
6. Wieland H.A., Michaelis M., Kirschbaum B.J., Rudolphi K.A. Osteoarthritis - an untreatable disease?. Nat Rev Drug Discov 2005, 4(4):331-344.
7. Little C.B., Barai A., Burkhardt D., et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60(12):3723-3733.
8. Neuhold L.A., Killar L., Zhao W., et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001, 107(1):35-44.
9. Racke M.K., Lovett-Racke A.E., Karandikar N.J. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010, 74(Suppl 1):S25-S30.
10. Kindrachuk J., Napper S. Structure-activity relationships of multifunctional host defence peptides. Mini Rev Med Chem 2010, 10(7):596-614.
11. Sugahara K.N., Teesalu T., Karmali P.P., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328(5981):1031-1035.
12. Wu W.K., Wang G., Coffelt S.B., Betancourt A.M., Lee C.W., Fan D., et al. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer 2010, 127(8):1741-1747.
13. Bidwell G.L., Raucher D. Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv Drug Deliv Rev 2010, 62(15):1486-1496.
14. Burger D., Molnarfi N., Weber M.S., et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 2009, 106(11):4355-4359.
15. Attur M.G., Dave M., Cipolletta C., et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 2000, 275(51):40307-40315.
16. Attur M., Al-Mussawir H.E., Patel J., et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor. J Immunol 2008, 181(7):5082-5088.
17. Gilliam M.B., Sherman M.P., Griscavage J.M., Ignarro L.J. A spectrophotometric assay for nitrate using NADPH oxidation by Aspergillus nitrate reductase. Anal Biochem 1993, 212(2):359-365.
18. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
19. Chevalier X., Goupille P., Beaulieu A.D., et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61(3):344-352.
20. Gouze E., Pawliuk R., Gouze J.N., et al. Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. Mol Ther 2003, 7(4):460-466.
21. Dinarello C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004, 4(4):378-385.
22. Evans C.H., Robbins P.D., Ghivizzani S.C., et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005, 102(24):8698-8703.
23. Dahlen E., Barchan K., Herrlander D., et al. Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis. J Immunotoxicol 2008, 5(2):189-199.
24. Kay J.D., Gouze E., Oligino T.J., et al. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med 2009, 11(7):605-614.
25. Palmer G., Guerne P.A., Mezin F., et al. Production of interleukin-1 receptor antagonist by human articular chondrocytes. Arthritis Res 2002, 4(3):226-231.
26. Palmer G., Burger D., Mezin F., et al. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 2004, 6(3):R181-R189.
27. Palmer G., Mezin F., Juge-Aubry C.E., Plater-Zyberk C., Gabay C., Guerne P.A. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis 2004, 63(1):43-49.
28. Aharoni R., Sonego H., Brenner O., Eilam R., Arnon R. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 2007, 112(2):110-119.
29. Grazioli V., Schiavo R., Casari E., Marzatico F., Baena R., Gaetani P. Antioxidant enzymatic activities and lipid peroxidation in cultured human chondrocytes from vertebral plate cartilage. FEBS Lett 1998, 431(2):149-153.
30. Tiku M.L., Shah R., Allison G.T. Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J Biol Chem 2000, 275(26):20069-20076.
31. Corvol M.T. The chondrocyte: from cell aging to osteoarthritis. Joint Bone Spine 2000, 67(6):557-560.
32. Dave M., Attur M., Palmer G., et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008, 58(9):2786-2797.
33. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274(31):21491-21494.
34. Mitchell P.G., Magna H.A., Reeves L.M., et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996, 97(3):761-768.
35. Skiles J.W., Gonnella N.C., Jeng A.Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr Med Chem 2004, 11(22):2911-2977.